View more in
Medical & Biotech

Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials

Posted by 
Benzinga
Benzinga
 2021-06-11
Cover picture for the article

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology Association annual meeting, the companies announced that three-month follow-up data of 22 patients...

www.benzinga.com

Comments / 0

Comments / 0